tbuckley/cabot-search huggingface dataset:
Patterns of recurrence after neoadjuvant docetaxel, cisplatin, and 5FU combined with resection and extended lymphadenectomy for locally advanced esophagogastric adenocarcinoma.
Authors: Lorenzo Ferri, Thierry Alcindor, Steven Ades, Abdullah Aloraini, Marie Vanhuyse, Jamil Asselh, Marc David, Michael P. Thirlwell
Journal: Journal of Clinical Oncology (2013)

e15044 Background: We have previously identified Docetaxel, Cisplatin, and 5FU (DCF) as a highly effective regimen in the neoadjuvant setting for locally advanced adenocarcinoma (ADC) of the esophagus and esophago-gastric junction (EGJ). However there is ongoing debate whether chemotherapy alone provides adequate local or regional control. We hypothesized that DCF combined with enhanced local surgical control would result in a low rate of local or regional recurrence. Methods: A prospective entered database of all esophageal/EGJ ADC pts resected at a high volume referral center was reviewed for cases treated with neoadjuvant DCF (Docetaxel 75mg/m2, Cisplatin 75mg/m2, 5FU 750mg/m2x120 hrs CIV) Q3weeks x3, followed by en-bloc resection with extended lymphadenectomy (D2). Follow up included physical exam Q3m x 2 yrs then Q6m, and endoscopy and CT chest/abdo/pelvis performed Q6 m. Recurrence was defined as: Local = biopsy on endoscopy; Regional = regional lymph nodes; Distant = distant organ or non-regional lymph nodes. Data presented as Median (Range). Results: Of 281 pts in the database, 89 (75%male, 63yrs(24-80)) underwent pre-op DCF and resection for locally advanced ADC (cT3 93%;cN+ 73%) of the EGJ (51%) or distal esophagus (49%) from 3/07-10/12. After overall follow-up of 37(6-72) months, 37 (42%) have recurred at 15(6-33) months. Sites of recurrence include Distant only in 29/37, Regional only in 5/37, and Regional and Distant in 3/37. First site of distant recurrence was peritoneum (14/37), liver (10/37), non-regional lymph nodes (10), brain/ovary/pleura (2 each), and bone(1). No patient had local recurrence alone. 3/5 patients with regional recurrence underwent salvage chemoradiotherapy and are alive without disease at 36 months (30-47) after recurrence. Conclusions: En-bloc resection with extended lymphadenectomy after DCF for locally advanced ADC of the esophagus and EGJ is associated with a low rate of local and regional recurrence. As vast majority of recurrences are distant, our data supports the notion that efforts to improve outcomes in these pts should concentrate on enhancing systemic, rather than local, therapy.
Red and Processed Meat Consumption and Risk for All-Cause Mortality and Cardiometabolic Outcomes
Authors: Dena Zeraatkar, Mi Ah Han, Gordon H. Guyatt, Robin W.M. Vernooij, Regina El Dib, Kevin Cheung, Kirolos Milio, Max Zworth, Jessica J. Bartoszko, Claudia Valli, Montserrat Rabassa, Yung Lee, Joanna Zajac, Anna Prokop-Dorner, Calvin Lo, Malgorzata M. Bala, Pablo Alonso-Coello, Steven E. Hanna, Bradley C. Johnston
Journal: Annals of Internal Medicine (2019)

This article has been corrected. The original version (PDF) is appended to this article as a Supplement. Background: Dietary guidelines generally recommend limiting intake of red and processed meat. However, the quality of evidence implicating red and processed meat in adverse health outcomes remains unclear. Purpose: To evaluate the association between red and processed meat consumption and all-cause mortality, cardiometabolic outcomes, quality of life, and satisfaction with diet among adults. Data Sources: EMBASE (Elsevier), Cochrane Central Register of Controlled Trials (Wiley), Web of Science (Clarivate Analytics), CINAHL (EBSCO), and ProQuest from inception until July 2018 and MEDLINE from inception until April 2019, without language restrictions, as well as bibliographies of relevant articles. Study Selection: Cohort studies with at least 1000 participants that reported an association between unprocessed red or processed meat intake and outcomes of interest. Data Extraction: Teams of 2 reviewers independently extracted data and assessed risk of bias. One investigator assessed certainty of evidence, and the senior investigator confirmed the assessments. Data Synthesis: Of 61 articles reporting on 55 cohorts with more than 4 million participants, none addressed quality of life or satisfaction with diet. Low-certainty evidence was found that a reduction in unprocessed red meat intake of 3 servings per week is associated with a very small reduction in risk for cardiovascular mortality, stroke, myocardial infarction (MI), and type 2 diabetes. Likewise, low-certainty evidence was found that a reduction in processed meat intake of 3 servings per week is associated with a very small decrease in risk for all-cause mortality, cardiovascular mortality, stroke, MI, and type 2 diabetes. Limitation: Inadequate adjustment for known confounders, residual confounding due to observational design, and recall bias associated with dietary measurement. Conclusion: The magnitude of association between red and processed meat consumption and all-cause mortality and adverse cardiometabolic outcomes is very small, and the evidence is of low certainty. Primary Funding Source: None. (PROSPERO: CRD42017074074)
Abstract 14231: Statin Use, but Not Low Density Lipoprotein Cholesterol Levels, is Associated With Better Survival in Japanese Patients With Ischemic Heart Failure -Interim Analysis of the CHART-2 Study
Authors: Kotaro Nochioka, Nobuyuki Shiba, Masanobu Miura, Hiroaki Shimokawa
Journal: Circulation (2011)

Background: Statins are widely used in patients with ischemic heart disease. However, the association between statin use and low density lipoprotein cholesterol (LDL-C) levels in patients with isch...
Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Authors: J.M. Trigo Perez, E. Felip, P. Brunsvig, A. Helland, N. Viñolas, S. Ponce Aix, E. Carcereny Costa, M. Domine Gomez, E. Arriola, R. Garcia Campelo, J. Spicer, J.R. Thompson, A.L. Ortega Granados, R.J. Holt, J.B. Lorens, M. Shoaib, A. Siddiqui, E.V. Schmidt, M.J. Chisamore, M.G. Krebs
Journal: Annals of Oncology (2019)
Prevalence of chemotherapy use and its impact on overall survival in patients with bone and soft tissue sarcomas: A population-based analysis of 3746 patients
Authors: H H-F Loong, C.K.H. Wong, C.-W. Ho, L.K.S. Leung, T. Tse, S.S. Kwan, Y.-M. Lau
Journal: Annals of Oncology (2019)
Introducing the HemaSphere Controversies Series
Authors: Dennis A. Eichenauer, Jan Cools, Andreas Engert
Journal: HemaSphere (2019)

Diagnostics, treatment, response evaluation, and follow-up of hematologic diseases have changed considerably in recent years. Novel diagnostic techniques and improved staging tools allow an accurate biological and pathological characterization and a precise risk group allocation in various diseases.1–3 The increasing knowledge of crucial pathways involved in onset, maintenance and progression of hematologic diseases has resulted in the development and introduction of targeted therapies such as monoclonal antibodies,4 antibody-drug conjugates,5 kinase inhibitors,6 CAR-T cells7,8 and others. These drugs are given either alone or in combination with conventional chemotherapy and have significantly improved the prognosis of many malignant hematologic diseases.9,10 In a number of malignancies, response assessment and follow-up are no longer restricted to physical examination, evaluation of standard laboratory parameters and radiological examinations, but also include the detection of circulating tumor DNA or minimal residual disease in case an appropriate marker is available.2,11 Hence, the rapid development in both, basic and clinical research has led to unquestionable improvements for a multitude of patients, but also generated novel questions and controversies with regard to diagnostics, therapy and follow-up. In an attempt to address the current challenges in the field of hematology, HemaSphere has launched an article series termed “Controversies in Hematology”.12 Each article will be written by a panel of experts from different cooperative groups focusing on a particular disease. In the introduction part of these articles, the current knowledge obtained from recent prospective studies is described briefly. Thereafter, the most relevant unsolved questions are presented and discussed. Those may include the choice of the optimal diagnostic and staging procedures, for example, genetic examinations in leukemia and imaging in lymphoma.1,2 Factors influencing the choice of first-line treatment and salvage approaches, such as stage at diagnosis, age, risk-benefit ratio and others, as well as the pros and cons of different treatment options in the respective clinical situation (first-line treatment, salvage treatment, consolidation treatment) are being discussed more extensively. Of note, the role of novel agents is highlighted as it is often not defined sufficiently. Last, open questions regarding follow-up examinations are addressed, including the time interval between follow-up visits, the extent of each follow-up visit and possible novel ways to optimize the detection of disease recurrence and therapy-related late effects. Taken together, articles of the HemaSphere controversies series will provide a comprehensive overview of the most relevant issues discussed in the field of hematology.
Gastric Decontamination in Patient With Gastric Stapling
Authors: G A Bucholtz, R F Lockey
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A tumor microenvironment responsive biodegradable CaCO<sub>3</sub>/MnO<sub>2</sub>- based nanoplatform for the enhanced photodynamic therapy and improved PD-L1 immunotherapy
Authors: Yanlei Liu, Yunxiang Pan, Wen Cao, Fangfang Xia, Bin Liu, Jiaqi Niu, Gabriel Alfranca, Xiyang Sun, Lijun Ma, Jesus Martinez de la Fuente, Jie Song, Jian Ni, Daxiang Cui
Journal: Theranostics (2019)

The low efficiency of photodynamic therapy (PDT) is caused by tumor hypoxia and the adaptive immune resistance/evasion of tumor cells, while the currently emerging immune checkpoint therapy restores the intrinsic immune capacities but can't directly attack the tumor cells. Methods: Herein we report an integrated nanoplatform that combines PDT with immunotherapy to enhance photodynamic therapeutic effects and simultaneously inhibit tumor cells resistance/evasion. To achieve this, we fabricated Mn@CaCO3/ICG nanoparticles and loaded them with PD-L1-targeting siRNA. Results: Thanks to the protection of CaCO3 on the loaded ICG and the oxygen produced by MnO2, an enhanced photodynamic therapeutic effect in vitro was observed. In vivo experiments demonstrated that the nanoplatform could efficiently deliver the loaded drug to the tumor tissues and significantly improve tumor hypoxia, which further contributes to the therapeutic effect of PDT in vivo. Moreover, the synergistic benefits derived from the siRNA, which silenced the checkpoint gene PD-L1 that mediates the immune resistance/evasion, resulted in a surprising therapeutic effect to rouse the immune system. Conclusions: The combination treatment strategy has great potential to be developed as a new and robust method for enhanced PDT therapy with high efficiency and a powerful antitumor immune response based on PD-L1 blockade.
Site-Directed Pegylation at Specific Sites Significantly Prolongs the Half-Life of A1A2A3-VWF By Markedly Attenuating LRP1-Mediated Clearance
Authors: Jamie M O'Sullivan, Judicael Fazavana, Alain Chan, Niamh Cooke, Virginie Terraube, Justin Cohen, Debra D Pittman, Orla Cunningham, Matthew Lambert, James S O'Donnell
Journal: Blood (2018)
Microsatellite instability testing and lynch syndrome screening for colorectal cancer patients through tumour sequencing
Authors: L. Liu, C. Garbutt, M. Golkaram, S. Kaplan, M. Martins, S. Casino, A. Mansinho, D. Macedo, C. Alvim, A.L. Costa, A. Fernandes, C. Ferreira, F. Aldeia, A. Quintela, L. Costa, A. So, S. Zhang, T. Pawlowski
Journal: Annals of Oncology (2019)
First real life data on durvalumab after definitive concomitant chemoradiotherapy (cCRT) in unresectable stage (St) III non-small cell lung cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) temporary authorization of use (ATU)
Authors: V. Avrillon, S. Bota Ouchlif, P. Merle, E. Pichon, A.T. Stancu, C. Chouaid, C. Sire, H. Boudabous, A. Lagrange, M. Sabatini, G. Eberst, P. Boisselier, A. Gourion, A. Lion, A. Lahouegue, K. Belkhiria, I. de La Porte, M. Urbieta, F. Mornex, N. Girard
Journal: Annals of Oncology (2019)
Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study
Authors: M. van der Heijden, T. Powles, D. Petrylak, R. de Wit, K. Chi, A. Necchi, C.N. Sternberg, N. Matsubara, H. Nishiyama, D. Castellano, S. Hussain, A. Bamias, R. Hozak, R. Rhodes, M.S. Xia, E. Rasmussen, A. Aggarwal, S. Wijayawardana, K.M. Bell-McGuinn, A. Drakaki
Journal: Annals of Oncology (2019)
Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?
Authors: Johan Karlsson Wallman, Elisabeth Mogard, Jan Marsal, Kristofer Andréasson, Anna Jöud, Mats Geijer, Lars Erik Kristensen, Elisabet Lindqvist, Tor Olofsson
Journal: Annals of the Rheumatic Diseases (2019)

The link between spondyloarthritis and inflammatory bowel disease (IBD) is well-established, with 5%–10% of patients with axial spondyloarthritis (axSpA) having concurrent IBD. Beyond that, ~50%–60% display microscopic gut inflammation,1 and faecal calprotectin (F-calprotectin) is elevated,2 although neither of these findings have been clearly linked to gut symptoms.1 2 Nevertheless, >50% of patients with ankylosing spondylitis (AS) report frequent gut pain/diarrhoea.3 This calls for investigating other potential causes, including irritable bowel syndrome (IBS), for which data in axSpA remain sparse. IBS (general population prevalence ~11%4) is thought to arise through mechanisms similar to fibromyalgia, common in axSpA (affecting up to 25% versus ~2% in the general population).

We aimed to compare the prevalence of gut symptoms meeting ROME III criteria for IBS between patients with axSpA and healthy controls.5 Hence, 182 consecutive patients with well-characterised axSpA without known IBD from the population-based SPARTAKUS study,2 and 50 controls, frequency-matched for sex/age, without rheumatic disease or IBD, were included (online supplementary table S1). For SPARTAKUS protocol/classification algorithm details, see online supplementary file 1.### Supplementary data

[annrheumdis-2019-216134supp001.pdf] 

We found that gut symptoms meeting IBS criteria were significantly more frequent among patients with axSpA (30%) than controls (16%; OR: 2.5 (95% CI 1.1 to 5.7); p=0.036) by sex/age-adjusted logistic regression (figure 1A). Additional adjustments for F-calprotectin levels and non-steroidal anti-inflammatory drug (NSAID)-use, respectively, as well as excluding patients/controls reporting ‘alarm symptoms’ (frequent bloody/black stools; unexplained weight-loss), yielded similar OR-estimates for the patients/controls difference (online supplementary file 1).



Figure 1 
Proportions of patients with axSpA and controls reporting gut symptoms …
Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Authors: Kristy Drafahl, David C Smith, Cristen Graham, Christine Glynn, Cindy Spittle, Scott Verrow, Victor M. Rivera, Shouryadeep Srivastava, Kevin Hawkins, Chad Galderisi
Journal: Blood (2018)
Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx
Authors: J. Sparano, R.J. Gray, D. Makower, K. Albain, T.J. Saphner, S. Badve, L. Wagner, C. Mihalcioiu, C. Desbiens, D.F. Hayes, E.C. Dees, C. Geyer, J. Olson, W.C. Wood, T. Lively, S. Paik, M. Ellis, J.S. Abrams, G.W. Sledge
Journal: Annals of Oncology (2019)
Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy
Authors: W.V.D. Meer, E.A. Basak, D.P. Hurkmans, M.W.J. Schreurs, E. Oomen-de Hoop, A.A.M. Van der Veldt, S. Bins, A. Joosse, S.L. Koolen, R. Debets, R.P. Peeters, J.G. Aerts, R.H. Mathijssen, M. Medici
Journal: Annals of Oncology (2019)
The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
Authors: F. Passiglia, E. Capelletto, F. Grossi, P. Bidoli, D. Galetta, A. Follador, G.P. Valmadre, C. Defferrari, O. Caffo, A. Bearz, I. Colantonio, V. Gregorc, V. Scotti, F. Cognetti, L. Cordero, F. Arizio, S. Novello, V. Torri, G. Scagliotti
Journal: Annals of Oncology (2019)
Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Authors: N. Normanno, J. Fairley, M. Cheetham, M.G. Denis, E. Dequeker, C. Keppens, F. Fenizia, S. Patton, E. Rouleau, E. Schuuring, K. Van Casteren, Z. Deans
Journal: Annals of Oncology (2019)
Rescue from Stx2-Producing E. coli-Associated Encephalopathy by Intravenous Injection of Muse Cells in NOD-SCID Mice
Authors: Ryo Ozuru, Shohei Wakao, Takahiro Tsuji, Naoya Ohara, Takashi Matsuba, Muhammad Y. Amuran, Junko Isobe, Morio Iino, Naoki Nishida, Sari Matsumoto, Kimiharu Iwadate, Noriko Konishi, Kaori Yasuda, Kosuke Tashiro, Misato Hida, Arisato Yadoiwa, Shinsuke Kato, Eijiro Yamashita, Sohkichi Matsumoto, Yoichi Kurozawa, Mari Dezawa, Jun Fujii
Journal: Molecular Therapy (2019)

Shiga toxin-producing Escherichia coli (STEC) causes hemorrhagic colitis, hemolytic uremic syndrome, and acute encephalopathies that may lead to sudden death or severe neurologic sequelae. Current treatments, including immunoglobulin G (IgG) immunoadsorption, plasma exchange, steroid pulse therapy, and the monoclonal antibody eculizumab, have limited effects against the severe neurologic sequelae. Multilineage-differentiating stress-enduring (Muse) cells are endogenous reparative non-tumorigenic stem cells that naturally reside in the body and are currently under clinical trials for regenerative medicine. When administered intravenously, Musecells accumulate to the damaged tissue, where they exert anti-inflammatory, anti-apoptotic, anti-fibrotic, and immunomodulatory effects, and replace damaged cells by differentiating into tissue-constituent cells. Here, severely immunocompromised non-obese diabetic/severe combined immunodeficiency (NOD-SCID) mice orally inoculated with 9 × 109 colony-forming units of STEC O111 and treated 48 h later with intravenous injection of 5 × 104 Muse cells exhibited 100% survival and no severe after-effects of infection. Suppression of granulocyte-colony-stimulating factor (G-CSF) by RNAi abolished the beneficial effects of Muse cells, leading to a 40% death and significant body weight loss, suggesting the involvement of G-CSF in the beneficial effects of Muse cells in STEC-infected mice. Thus, intravenous administration of Muse cells could be a candidate therapeutic approach for preventing fatal encephalopathy after STEC infection.
Detectability of druggable gene fusions by amplicon-based next generation sequencing in LC-SCRUM-Japan
Authors: Tomohiro Sakamoto, Shingo Matsumoto, Shinnosuke Ikemura, Hidetoshi Itani, Masato Shingyoji, Toru Kojima, Masaharu Shinkai, Takashi Kohno, Koji Tsuta, Koichi Goto
Journal: Annals of Oncology (2016)
Predictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada
Authors: P. Blanchette, M. Lam, L. Richard, B. Allen, S. Shariff, T. Vandenberg, K. Pritchard, K. Chan, A. Louie, D. Desautels, J. Raphael, C. Earle
Journal: Annals of Oncology (2019)
What If Miro’s Dots and Lines Are Not Simply Dots and Lines?—Reply
Authors: Shaurya Taran, Allan S. Detsky
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Functional analysis of tumour infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B
Authors: H. Kawaji, M. Kubo, Y. Motoyama, A. Shimazaki, S. Hayashi, K. Kurata, M. Yamada, K. Kaneshiro, M. Kai, M. Nakamura
Journal: Annals of Oncology (2019)
The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis
Authors: S. Mohd Sazlly Lim, A. Zainal Abidin, S.M. Liew, J.A. Roberts, F.B. Sime
Journal: Journal of Infection (2019)